trending Market Intelligence /marketintelligence/en/news-insights/trending/4SpCgOEiLD5rkjWbSoTrrg2 content esgSubNav
In This List

Processa Pharmaceuticals to undertake 1-for-7 reverse stock split

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Processa Pharmaceuticals to undertake 1-for-7 reverse stock split

Processa Pharmaceuticals Inc. will undertake a 1-for-7 reverse stock split of its issued and outstanding common stock, effective Dec. 23.

Processa Pharmaceuticals' shareholders approved the reverse stock split Nov. 7, and the move will help reduce the company's common stock issued and outstanding to approximately 5.5 million from 38.4 million.

The company's shares will continue trading on the OTCQB market under the ticker PCSA.

The Hanover, Md.-based pharmaceutical company is developing medicine for a skin condition known as necrobiosis lipoidica.